The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Novartis announced that Cosentyx (secukinumab) received US Food and Drug Administration (FDA) approval for treating paediatric patients 12 years and older with moderate to severe hidradenitis ...

Approval was supported by adult HS and psoriasis clinical trials, pharmacokinetic modeling, and data from established pediatric indications. The Food and Drug Administration (FDA) has approved ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

Please provide your email address to receive an email when new articles are posted on . This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis ...

Basel, March 13, 2026 – Novartis announced today that Cosentyx ® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ...

Oct 24 (Reuters) - Novartis AG: * NOVARTIS RECEIVES APPROVAL FOR COSENTYX LABEL UPDATE IN EUROPE TO INCLUDE DOSING FLEXIBILITY IN ANKYLOSING SPONDYLITIS Source text for Eikon: Further company coverage ...

Atopic dermatitis and psoriasis are well-established battlefields for anti-inflammatory biologic drugs. Now, two drugmakers are preparing to launch products in a lesser-known disease area with ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade 1-3 HS often emerges around puberty, underscoring importance of early ...